Bristol-Myers Squibb Co (BMY.N) Key Developments | Reuters.com
Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

70.32USD
27 Jun 2016
Change (% chg)

$-0.29 (-0.41%)
Prev Close
$70.61
Open
$70.39
Day's High
$71.12
Day's Low
$70.09
Volume
2,221,872
Avg. Vol
1,848,082
52-wk High
$75.12
52-wk Low
$51.82

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Co increases FY 2016 guidance
Thursday, 28 Apr 2016 06:58am EDT 

Bristol-Myers Squibb Co:Increases FY 2016 GAAP EPS guidance range from $2.30 - $2.40 to $2.37 - $2.47.Also increases FY 2016 non-GAAP EPS guidance range from $2.30 - $2.40 to $2.50 - $2.60.  Full Article

Bristol-Myers Squibb Co completes previously announced acquisition of Padlock Therapeutics Inc
Friday, 1 Apr 2016 04:15pm EDT 

Bristol-Myers Squibb Co:Has completed the previously announced planned acquisition of Padlock Therapeutics Inc.  Full Article

Bristol-Myers Squibb Co to acquire Padlock Therapeutics, Inc
Wednesday, 23 Mar 2016 06:59am EDT 

Bristol-Myers Squibb Co:To acquire padlock therapeutics, inc.Says transaction has been approved by the boards of directors of both companies and by the stockholders of padlock.Deal includes additional contingent consideration of up to $375 million upon achievement by Bristol Myers Squibb-of certain events.  Full Article

Bristol-Myers Squibb Co announces quarterly dividend
Thursday, 3 Mar 2016 04:15pm EST 

Bristol-Myers Squibb Co:Declares quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock of the corporation.Says next quarterly dividend will be payable on May 2, 2016, to stockholders of record at the close of business on April 1.  Full Article

Bristol-Myers Squibb Co receives two positive CHMP opinions for opdivo
Friday, 26 Feb 2016 07:13am EST 

Bristol-Myers Squibb Co:Receives two positive CHMP opinions for opdivo for patients with previously treated advanced non-squamous non-small cell lung cancer and renal cell carcinoma.  Full Article

Bristol-Myers Squibb Co and Dana-Farber Cancer Institute enter into research agreement
Tuesday, 16 Feb 2016 06:59am EST 

Bristol-Myers Squibb Co:Bristol Myers Squibb-and dana-farber cancer institute enter into a collaboration agreement as part of U.S. immuno-oncology rare population malignancy research program.As part of i-o rpm program, co, dana-farber cancer institute will Conduct A Range of early phase clinical studies.  Full Article

Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Monday, 1 Feb 2016 06:55am EST 

Bristol-Myers Squibb Co:Says the company and Pfizer Inc have entered into a collaboration agreement with Portola Pharmaceuticals Inc to develop and commercialize the investigational agent andexanet alfa in Japan.Under the terms of the agreement, portola will receive an upfront payment of $15 million.Bristol-myers Squibb and Pfizer will co-fund with Portola the development and commercialization of andexanet alfa in japan.Portola will retain rights to andexanet Alfa outside of japan and remain responsible for the manufacturing supply.Under terms, Portola will get potential regulatory milestones of $20 million and sales-based milestones of $70 million.  Full Article

Bristol-Myers Squibb Co says European commission approves Daklinza (daclatasvir)
Thursday, 28 Jan 2016 12:41pm EST 

Bristol-Myers Squibb Co:Says European Commission approves Daklinza (daclatasvir) for treatment of Genotype 1, 3 and 4 chronic hepatitis C patients with HIV coinfection, advanced cirrhosis and post-liver transplant recurrence of HCV.Says updated label provides additional treatment options for multiple HCV patient populations.  Full Article

Bristol-Myers Squibb Co gives FY 2016 EPS guidance
Thursday, 28 Jan 2016 06:59am EST 

Bristol-Myers Squibb Co:Expect FY 2016 expects FY 2016 GAAP and non-GAAP EPS guidance range at $2.30 - $2.40.  Full Article

Dual Therapeutics announces oncology strategic collaboration with Bristol-Myers Squibb
Friday, 8 Jan 2016 08:00am EST 

Dual Therapeutics:Says strategic collaboration with Bristol-Myers Squibb to advance small molecule compounds for treatment of cancer and other diseases.Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize the small molecule therapeutics discovered by Dual Therapeutics.  Full Article

BRIEF-Bristol-Myers Squibb's Opdivo gets breakthrough therapy approval from FDA

* Bristol Myers Squibb Co - intends to file marketing application with health authorities based on results from phase 2 study ca209-275, other data